Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda
Depression symptoms and cognitive function among individuals with advanced HIV infection initiating HAART in Uganda
复制标题
DOI：
10.1186/1471-244x-10-44
复制
发表时间：
2010-06-10
期刊：
影响因子：
4.4
通讯作者：
Sacktor, Ned
中科院分区：
文献类型：
--
作者：
Nakasujja, Noeline;Skolasky, Richard L.;Sacktor, Ned
背景：在HIV感染者中，抑郁是最常见的精神障碍。在撒哈拉以南非洲，艾滋病毒患者中抑郁症状和认知功能障碍的存在尚未得到充分研究。启动高活性抗逆转录病毒治疗（HAART）的流行率和随着时间的推移，抑郁症状和认知功能障碍的HIV阳性individual.Methods的变化可能会产生影响：我们招募了102名HIV阳性个体的认知功能障碍的风险谁是启动HAART和25名HIV阴性个体匹配的年龄和教育。抑郁症采用流行病学研究中心抑郁量表（CES-D）进行评估。神经认知评估包括国际艾滋病痴呆量表（IHDS），一个8测试神经心理电池和纪念斯隆-凯特琳量表。结果：在3次门诊访视中，HIV阳性组CES-D评分> 16分的人数均多于HIV阴性组（分别为54% Vs 28%; 36% Vs 13%;和30% Vs 24%;所有p < 0.050或2.86，95% CI：1.03，7.95，p = 0.044）。HIV阳性组有较高的认知功能障碍的可能性（OR 8.88，95% CI 2.64，29.89，p < 0.001）。与HIV阴性组相比，HIV阳性组的CES-D（p = 0.002）和IHDS（p = 0.001）平均评分显著降低。临床记忆Sloan Kettering评分和抑郁症状（p = 0.310）在baseline.Conclusion：抑郁障碍是不同的和常见的认知功能受损的艾滋病患者之间没有关联。因此，艾滋病毒护理中的个人应进行筛查和抑郁症治疗。
Background: Among patients with HIV infection, depression is the most frequently observed psychiatric disorder. The presence of depressive symptoms and cognitive dysfunction among HIV patients has not been well studied in Sub-Saharan Africa. Initiation of highly active antiretroviral therapy (HAART) may have an effect on the prevalence and the change over time of depression symptoms and cognitive impairment among HIV-positive individuals.Methods: We recruited 102 HIV-positive individuals at risk of cognitive impairment who were initiating HAART and 25 HIV-negative individuals matched for age and education. Depression was assessed using the Centre for Epidemiologic Studies Depression Scale (CES-D). Neurocognitive assessment included the International HIV Dementia Scale (IHDS), an 8 test neuropsychological battery and the Memorial Sloan Kettering scale. Assessments were carried out at 0, 3 and 6 months.Results: The HIV-positive group had more respondents with CES-D score > 16 than the HIV-negative group at all 3 clinic visits (54% Vs 28%; 36% Vs 13%; and 30% Vs 24% respectively; all p < 0.050 OR 2.86, 95% CI: 1.03, 7.95, p = 0.044). The HIV positive group had higher likelihood for cognitive impairment (OR 8.88, 95% CI 2.64, 29.89, p < 0.001). A significant decrease in the mean scores on the CES-D (p = 0.002) and IHDS (p = 0.001) occurred more in the HIV-positive group when compared to the HIV-negative group. There was no association between clinical Memorial Sloan Kettering score and depression symptoms (p = 0.310) at baseline.Conclusion: Depression symptomatology is distinct and common among cognitively impaired HIV patients. Therefore individuals in HIV care should be screened and treated for depression.